Latest metastatic melanoma Stories
Researchers with UCLA's Jonsson Comprehensive Cancer Center have discovered a way to amp up the power of killer T-cells, called CD8 cells, making them more functional for longer periods of time and boosting their ability to multiply and expand within the body to fight melanoma, a new study has found.
The U.S. Food and Drug Administration today approved the use of ipilimumab for the treatment of previously treated metastatic melanoma.
Researchers have found that a novel form of personalized therapy that genetically engineers a patient's own anti-tumor immune cells to fight tumors could treat metastatic melanoma and metastatic synovial cell sarcoma.
INDIANAPOLIS, Dec. 13, 2010 /PRNewswire/ -- Eli Lilly and Company announced today that it has suspended its global Phase III study evaluating tasisulam, an investigational, small-molecule anti-cancer compound, as a second-line treatment for those with unresectable or metastatic melanoma.
Complete remission of cancer is what many of the more than 68,000 patients who will be diagnosed with melanoma this year would love to hear.
A potent anti-tumor gene introduced into mice with metastatic melanoma has resulted in permanent immune reconfiguration and produced a complete remission of their cancer.
SAN DIEGO, Oct. 11 /PRNewswire/ -- More than 120 cancer survivors and caregivers, cancer-treating physicians, and patient advocates gathered in San Diego to share their ProleukinÂ® (aldesleukin for injection) treatment experiences.
Hoag Memorial Hospital Presbyterian recently announced encouraging clinical study results for patient-specific vaccine therapy to treat metastatic melanoma.
HACKENSACK, N.J., Sept.
Use of an experimental targeted drug to treat metastatic melanoma tumors with a specific genetic signature was successful in more than 80 percent of patients in a phase 1 clinical trial. Results of the trial of PLX4032, an inhibitor of a protein called BRAF that is overactive in more than half of all melanomas.
- A person in a secondary role, specifically the second most important character (after the protagonist).